Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 5 | EJNMMI Radiopharmacy and Chemistry

Fig. 5

From: Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β

Fig. 5

[18F]TZ-Z09591 uptake in 6wk CCl4 mice. A Liver and spleen uptake of [18F]TZ-Z09591 (at a concentration of 0,6 µg or 3 µg) and blocking study, in 6 weeks CCl4 treated mice compared to control mice. B Alanine aminotransferase (p-ALAT) and aspartate aminotransferase (p-ASAT) levels in the plasma of CCl4 mice compared to control mice. C Ex vivo autoradiograms of [18F]TZ-Z09591 binding, and blocking study, in the liver (Li), muscle (Mu), and spleen (Sp). D Representative Sirius Red staining images of liver from CCl4 treated and control mice (5.0 × magnification). Results from six weeks CCl4 treated mice are represented in red (nCCl4 = 13, including n = 4 0,6 µg [18F]TZ-Z0959, n = 4, 3 µg [18F]TZ-Z0959, and n = 5 pretreated mice) and from control mice in blue (nctrl = 9, including n = 4 0,6 µg [18F]TZ-Z0959 and n = 2 pretreated mice). Data are expressed as mean ± 1 SD. * means p < 0.05 and ** means p < 0.01. CCl4, carbon tetrachloride; SUV, standardized uptake value; p-ALAT, plasma alanine aminotransferase; p-ASAT, plasma aspartate transaminase

Back to article page